Completed PHASE2 INTERVENTIONAL 5-arm NCT02216656

Phase 2 Study of KHK7580

A Randomized, Double-blind, Parallel-group, Dose-finding Study of KHK7580 for Secondary Hyperparathyroidism Patients Receiving Hemodialysis

Sponsor: Kyowa Kirin Co., Ltd.

Conditions Secondary Hyperparathyroidism

Interventions KHK7580 high dose KHK7580 low dose KHK7580 middle dose KRN1493 Placebo

Updated 8 times since 2017 Last updated: Jul 8, 2018 Started: Jul 31, 2014 Primary completion: Feb 28, 2015 Completion: Feb 28, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Secondary Hyperparathyroidism, this trial is completed. The trial is conducted by Kyowa Kirin Co., Ltd. and has accumulated 8 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Aug 2019 — Jan 2021 [monthly]

Completed PHASE2
Aug 2018 — Aug 2019 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Aug 2018 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jul 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Kyowa Kirin Co., Ltd.

Data source: Kyowa Kirin Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tokyo, Japan